Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
07:00am, Tuesday, 15'th Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, the Comp
Alnylam to Webcast Virtual R&D Day
08:00am, Tuesday, 08'th Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the I
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company's Approved Therapies
07:30am, Monday, 07'th Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two new reports: the second annual update on its Patient Access
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C
Reasons Alnylam Is a Top Biotech Stock to Buy Right Now
08:24am, Monday, 30'th Nov 2020
The company's rare disease treatments are a huge success and there will probably be a lot more of them.
Alnylam's RNAi Therapies Make It A Buy
07:11am, Saturday, 28'th Nov 2020
Revenue is growing at a high percentage rate, but on a small base. Heavy investment in R&D will pay off as the decade progresses.
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
08:00am, Wednesday, 25'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasd
Alnylam Seeing A Rebound In Onpattro And Encouraging Early-Stage Hypertension Data
11:42pm, Monday, 16'th Nov 2020
Alnylam exceeded third-quarter sales expectations, with a stronger-than-expected recovery in Onpattro and healthy Givlaari sales. Another look at the Phase I ALN-AGT study showed double-digit blood pr
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q3 2020 Results - Earnings Call Transcript
04:16pm, Thursday, 05'th Nov 2020
Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q3 2020 Results - Earnings Call Transcript
Were These Hedge Funds Wrong About Alnylam Pharmaceuticals, Inc. (ALNY)?
01:14pm, Tuesday, 03'rd Nov 2020
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has won the 2020 Prix Galien USA Award for Best Biotechnology
Alnylam Named a Top Biopharma Employer by Science Magazine
03:06pm, Thursday, 29'th Oct 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that, for the second year in a row, Science magazine has named t
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
01:24pm, Tuesday, 25'th Aug 2020
Over a dozen regenerative medicine drugs have been launched, generating revenues approaching $4 billion in 2019.
Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease
11:30am, Monday, 17'th Aug 2020
Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously a
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
08:30am, Saturday, 15'th Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
